ÂÜÀòÂÒÂ×

Andreas Wallnoefer currently serves as a Special Advisor at JEITO since September 2024, and has been involved in biotech consulting through Andreas Wallnöfer Life Sciences Consulting Ltd. since 2015, where advisory roles include strategy, fundraising, M&A, and regulatory authority interactions. Previously, Andreas held multiple positions at Roche from 2001 to 2015, culminating in the role of Global Head Roche Pharma pRED Development, overseeing over 450 staff and spearheading significant clinical initiatives. As General Partner at BioMedPartners from 2016 to 2021, Andreas contributed to various successful ventures, including acquisitions and IPOs. Education includes an Executive MBA from IMD and a PhD in Pharmacology from the University of Basel. Current non-executive roles also include EyeBio Ltd. in London and leadership positions within the Singapore A-STAR Drug Development Center.